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Key questions
What is already known about this subject?
 ► Early experience with transcatheter mitral valve re-
placement (TMVR) identified certain challenges spe-
cific to this field. While conclusive randomised trials 
in the field are under way, contemporary outcomes 
of isolated surgical bioprosthetic MVR are lacking 
and can be used as benchmarks for these emerging 
TMVR therapies.
What does this study add?
 ► In-hospital mortality of isolated bioprothestic MVR 
improved overtime (7.8% in 2003 to 4.7% in 2014, 
p trend=0.016), but surgery remained associated 
with significant morbidity, lengthy hospitalisations 
and high cost of care.
How might this impact on clinical practice?
 ► These contemporary outcome data on isolated bi-
oprothestic mitral valve replacement may serve as 
benchmarks for TMVR.
AbstrAct
Background Early experience with transcatheter 
mitral valve replacement (TMVR) highlighted several 
investigational challenges related to this novel therapy. 
Conclusive randomised clinical trials in the field may, 
therefore, be years ahead. In the interim, contemporary 
outcomes of isolated surgical bioprosthetic mitral valve 
replacement (MVR) can be used as a benchmark for the 
emerging TMVR therapies.
Methods We used the nationwide inpatient sample 
to examine recent trends and outcomes of surgical 
bioprosthetic MVR for mitral regurgitation (isolated and 
combined).
Results 21 007 patients who had bioprosthetic MVR 
between 2003 and 2014 were included. Of those, 30% 
had isolated MVR and 70% had concomitant cardiac 
surgical procedure(s). In patients who underwent isolated 
bioprothestic MVR, mean age was 68±13, and females 
were the majority (58.4%). Most of these procedures were 
performed at teaching institutions (71.3%) and during an 
elective admission (64%). In-hospital mortality improved 
during the study period (7.8% in 2003 to 4.7% in 2014, 
p trend=0.016). Postoperative morbidities were common; 
permanent pacemaker 11.7%, stroke 2.4%, new dialysis 
4.9% and blood transfusion 41.6%. Mean length of stay 
was 13±12 days, and 27.2% of patients were discharged 
to an intermediate care of rehabilitation facility. Cost of 
hospitalisation was $62 443±50 997.
Conclusions Isolated bioprosthetic MVR for mitral 
regurgitation is performed infrequently but is associated 
with significant in-hospital morbidity and mortality and 
cost in contemporary practice. These data are useful as 
benchmarks for the evolving TMVR therapies.
The steady success of transcatheter aortic 
valve replacement (TAVR) has inspired an 
explosion of clinical investigations aiming 
at a matching success in transcatheter thera-
pies for mitral regurgitation (MR), especially 
in light of the consistent data showing that 
MR is undertreated worldwide.1–3 Although 
surgical treatment of MR has evolved to 
primarily one of repair, not replacement, 
early experience with transcatheter mitral 
repair technologies suggested that a large 
number of patients might be better suited 
for transcatheter mitral valve replacement 
(TMVR) than repair, fueling an increasing 
interest in TMVR.2 There are currently >30 
dedicated TMVR systems in development, 
but only a handful have reached the early 
feasibility study (EFS) stages.3
The first reports of TMVR with various 
transcatheter platforms have raised concerns 
about the safety of this therapy with an 
average 30-day mortality rate of 23%.4 Never-
theless, the EFS of TMVR with the Tendyne 
valve (Abbott, Roseville, Minnesota, USA) has 
recently reported very promising outcomes 
with an impressively low 30-day mortality at 
3.3%.5 Due to the complexity of mitral valve 
disease and the wide variability in its manage-
ment, clinical trials of TMVR are expected 
to face several challenges.6 In the interim, 
contemporary data on surgical MVR in 
patients with MR may serve as a benchmark 
for further investigations in the expanding 
TMVR field.3 4 7 We aim to use a nationwide 
representative sample to assess characteristics 
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Figure 1 Study flow chart.
and outcomes of patients with MR undergoing isolated 
bioprosthetic MVR in the USA between 2003 and 2014.
MetHods
The Nationwide Inpatient Sample (NIS) was used to 
derive patient-relevant information between January 
2003 and December 2014. The NIS is the largest publicly 
available all-payer administrative claims-based database 
and contains information about patient discharges from 
approximately 1000 non-federal hospitals in 45 states. It 
contains clinical and resource utilisation information on 
5–8 million discharges annually, with safeguards to protect 
the privacy of individual patients, physicians and hospi-
tals. These data are stratified to represent approximately 
20% of US inpatient hospitalisations across different 
hospital and geographic regions (random sample). 
National estimates of the entire US hospitalised popu-
lation were calculated using the Agency for Healthcare 
Research and Quality sampling and weighting method. 
The institutional review board approved the study and 
waived informed consent requirements because the data 
are derived from a nationwide deidentified database.
We used (International Classification of Diseases-Ninth 
Revision-Clinical Modification procedure code 35.23) to 
select patients aged 40 years and older who underwent 
bioprosthetic MVR during the study period. Patients who 
underwent redo valve surgery (codes 35.95), those with 
mitral stenosis (codes 394.0) or infective endocarditis 
(codes 421, 42.10, 42.11, 42.19, 03642, 09884, 11281, 
1154) or had codes for mitral valve repair or mechanical 
MVR during the same admission were excluded (figure 1). 
The outcomes of patients who underwent isolated valve 
replacement were then studied and compared with those 
of patients submitted for valve replacement combined 
with other cardiac surgery.
The trends of bioprosthetic MVR for MV during 
the 12-year study period were assessed using weighted 
numbers (national estimates). Baseline patients’ comor-
bidities and procedural characteristics were described 
for both the isolated and combined MVR groups. Trends 
of in-hospital mortality during the study period for 
both groups were described. Trend weights accounting 
for changes in the NIS sampling design are only avail-
able for data between 1998 and 2011. For 2012 and 
2014, trend weights were not available, and the standard 
survey weights were used. To estimate the cost of hospi-
talisation, the NIS data were merged with cost-to-charge 
ratios available from the Healthcare Cost and Utilization 
Project. We estimated the cost of each inpatient stay by 
multiplying the total hospital charge with cost-to-charge 
ratios. Postoperative morbidities, length of stay (LOS), 
disposition patterns and cost of care were also evalu-
ated. Patient-relevant descriptive statistics are presented 
as frequencies with percentages for categorical variables 
and as means with SD for continuous variables. Baseline 
characteristics were compared between the groups using 
a Pearson χ2 test for categorical variables and an inde-
pendent-samples t-test for continuous variables. Trends 
over time were examined using a Mann-Kendall test for 
trend (a non-parametric test to determine the presence 
and direction of a trend over time). All statistical analyses 
were performed using SPSS V.24 (IBM).
We also sought to identify independent predictors 
of in-hospital mortality in our study cohort. Hence, we 
entered 22 clinical, procedural and hospital character-
istics into univariate and multivariate logistic regression 
models to assess their possible predictive value of in-hos-
pital mortality after valve surgery (online supplementary 
e-table 1,2).
Results
Between 2003 and 2014, 21 007 patients who underwent 
bioprosthetic MVR for MR (representing a national esti-
mate of 103 709 patients), were included in our study. Of 
those, 14 727 (70.1%) underwent a concomitant cardiac 
surgical procedure. Utilisation of MVR for MR did not 
change significantly during the study period (figure 2). 
Patients who underwent a combined cardiac surgery 
were older (71±10 vs 68±13 years, p<0.001), had higher 
incidences of diabetes, atrial fibrillation, coronary and 
peripheral vascular disease, and chronic renal disease 
than those who underwent isolated MVR. However, 
history of sternotomy was more common in the isolated 
MVR group (table 1). Among patients who underwent 
combined MVR, coronary artery bypass grafting was the 
most common concomitant procedure (51.3%) followed 
by aortic valve replacement (31.5%) and Cox-Maze 
ablation (26.4%). There was a temporal trend towards 
treating sicker patients overtime evident by the increasing 
prevalence of key morbidities in both groups during the 
study period (online supplementary e-tables 1,2).
outcomes of isolated MVR
Among patients who underwent isolated MVR, in-hos-
pital mortality was 6.1%, but improved significantly 
during the study period from 7.8% in 2003 to 4.7% in 
2014 (ptrend=0.016) (figure 3). Stroke occurred in 
2.4%, vascular complications requiring surgical repair 
in 1.9% and new dialysis was required in 4.9% (table 2). 
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Figure 2 Utilisationt trends of bioprosthetic mitral valve replacement (MVR) for mitral regurgitation in the USA between 2003 
and 2014.
Also, 11.7% had a permanent pacemaker implantation 
postoperatively and 41.6% had blood transfusion. There 
was a temporal trend towards lower incidence of perma-
nent pacemaker implantation, but higher incidences of 
dialysis-requiring acute kidney injury and stroke during 
the study period (figure 4). Hospital LOS was >5 days in 
84.9% of patients with mean LOS of 13±12 days. Most 
patients were discharged home versus to intermediate 
care facility (66.1% vs 27.7%, p<0.001). Mean cost of 
hospitalisation was $62 443±50 997.
outcomes of combined MVR
Among patients who underwent MVR concomitant with 
other cardiac surgery, in-hospital mortality was 9.4% 
overall, but also improved during the study period (13.4% 
in 2003 to 8.3% in 2014, p trend=0.013) (figure 3). In 
these patients, stroke occurred in 2.6%, vascular compli-
cations requiring surgical repair in 2.3% and new dial-
ysis was initiated in 4.9%. Permanent pacemakers were 
implanted in 14.3% postoperatively. There was no statis-
tically significant change in the rates of major postopera-
tive morbidities in this cohort (figure 4). Approximately 
90% of patients stayed in the hospital over 5 days, with 
a mean LOS of 15±14 days. Intermediate care facilities 
were used in 35.4%. Mean cost of hospitalisation was $75 
469±57 052.
Predictors of in-hospital mortality
Multivariate logistic regression analyses were performed 
to identify predictors of in-hospital mortality in both 
groups. Variables included in the regression model 
included demographic and clinical characteristics, 
hospital attributes and insurance status. Among patients 
who underwent isolated MVR, the strongest predictors 
of in-hospital mortality were the need for ventricular 
assist device (OR 6.05, 95% CI 4.66 to 7.84), chronic 
renal failure (OR 2.42, 95% CI 1.88 to 3.12), liver disease 
(OR 2.27, 95% CI 1.15 to 4.47) and female gender (OR 
1.65, 95% CI 1.31 to 2.08). Other predictors are shown 
in online supplementary e-table 1. Among patients who 
underwent MVR concomitant with other cardiac surgery, 
the strongest predictors of in-hospital mortality were the 
need for ventricular assist device (OR 5.31, 95% CI 4.62 
to 6.09), liver disease (OR 3.02, 95% CI 2.14 to 4.25), 
concomitant tricuspid valve replacement (OR 2.01, 95% 
CI 1.39 to 2.92) and chronic renal failure (OR 1.83, 95% 
CI 1.58 to 2.13). Other significant predictors are shown 
in online supplementary e-tables 3,4.
the impact of gender on in-hospital outcomes
Females constituted the majority of patients undergoing 
MVR in this study, especially in the isolated MVR group. 
Compared with males, females who underwent MVR 
were less likely to be of white race and less likely to have 
chronic renal disease, coronary artery disease and prior 
sternotomy, but had higher prevalence of chronic obstruc-
tive lung disease and anaemia (online supplementary 
e-table 5. In-hospital mortality was higher in females than 
in males following isolated and combined MVR (6.9% vs 
5.0%, p=0.001, and 9.9% vs 8.8%, p=0.022, respectively). 
Females had higher incidences of acute kidney injury 
and blood transfusion, but similar rates of postoperative 
strokes and permanent pacemaker implantation (online 
supplementary e-table 6). Females also experienced 
longer length of stay, were more likely to be discharged 
to an intermediate care facility and accrued higher cost 
of the hospitalisation. In a multivariate logistical regres-
sion analysis adjusting for 22 demographic, clinical and 
hospital characteristics, female gender remained a signif-
icant independent predictor of in-hospital mortality (OR 
1.65, 95% CI 1.31 to 2.08 for isolated MVR, and OR 1.31, 
95% CI 1.15 to 1.48 for combined MVR) (online supple-
mentary e-tables 1,2).
disCussion
The main findings of the present study are (1) MVR for 
MR remains uncommon and is performed in conjunc-
tion with other cardiac surgery procedure in the majority 
of cases. (2) Patients who undergo MVR for MR have high 
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Table 1 Characteristics of patients undergoing surgical bioprosthetic mitral valve replacement (MVR) for mitral regurgitation 
between 2003 and 2014
Characteristic
All patients
(N=21 007
NE=103 709)
Combined MVR
(N=14 727
NE=72 680)
Isolated MVR
(N=6280
NE=31 029) P values
Age, mean (SD), years 70 (11) 71 (10) 68 (13) <0.001
Female, n (%) 11 511 (54.8) 7843 (53.3) 3668 (58.4) <0.001
Race, n (%) <0.0001
  White 13 946 (79.2) 9965 (80.8) 3981 (75.5)
  Black 1392 (7.9) 809 (6.6) 583 (11.1)
  Hispanic 1101 (6.3) 733 (5.9) 368 (7)
Medical comorbidity, n (%)
  Hypertension 11 893 (57) 8371 (57.2) 3522 (56.5) 0.337
  Diabetes 4435 (21.1) 3272 (22.2) 1163 (18.5) <0.001
  Prior sternotomy 1265 (6) 612 (4.2) 653 (10.4) <0.001
  Chronic pulmonary disease 5097 (24.3) 3565 (24.2) 1532 (24.4) 0.771
  Atrial fibrillation/flutter 13 484 (64.2) 9970 (67.7) 3514 (56) <0.001
  Anaemia 4095 (19.5) 2855 (19.4) 1240 (19.7) 0.548
  Coagulopathy 6151 (29.5) 4600 (31.4) 1551 (24.9) <0.001
  Conduction abnormalities 621 (3) 469 (3.2) 152 (2.4) <0.001
  Peripheral vascular disease 2125 (10.1) 1663 (11.3) 462 (7.4) <0.001
  Chronic renal disease 3476 (16.5) 2492 (16.9) 984 (15.7) 0.025
  Haemodialysis 381 (1.8) 261 (1.8) 120 (1.9) 0.491
  Coronary artery disease 9734 (46.3) 8165 (55.4) 1569 (25) <0.001
  Metastatic cancer 41 (0.2) 27 (0.2) 14 (0.2) 0.55
  Liver disease 360 (1.7) 250 (1.7) 110 (1.8) 0.777
  Liver cirrhosis 148 (0.7) 108 (0.7) 40 (0.6) 0.444
Concomitant procedures, n (%)
  Percutaneous coronary  
intervention
241 (1.1) 241 (1.6) 0 (0)
<0.001
  Coronary artery bypass 7562 (36) 7562 (51.3) 0 (0) <0.001
  Aortic valve replacement 4636 (22.1) 4636 (31.5) 0 (0) <0.001
  Tricuspid valve replacement 268 (1.3) 268 (1.8) 0 (0) <0.001
  Tricuspid valve repair 1279 (6.1) 1279 (8.7) 0 (0) <0.001
  Cox-Maze ablation 3883 (18.5) 3883 (26.4) 0 (0) <0.001
  Left atrial appendage ligation 2189 (10.4) 2189 (14.9) 0 (0) <0.001
  Open ASD/VSD repair 1147 (5.5) 1147 (7.8) 0 (0) <0.001
  IABP/LV assist device use 2257 (10.7) 1785 (12.1) 472 (7.5) <0.001
Hospital characteristics, n (%)
  Teaching hospital 14 726 (70.2) 10 262 (69.8) 4464 (71.3) 0.035
  Hospital bed size 0.478
   Small 1464 (7) 1033 (7) 431 (6.9)
   Medium 3785 (18.1) 2682 (18.2) 1103 (17.6)
   Large 15 719 (75) 10 988 (74.7) 4731 (75.5)
  Rural location 456 (2.2) 329 (2.2) 127 (2) 0.339
  Non-elective admission status,  
n (%)
8141 (38.8) 5883 (40) 2258 (36)
<0.001
  Surgery on day 0–1 of admission 11 221 (53.4) 7569 (51.4) 3652 (58.2) <0.001
Continued
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Characteristic
All patients
(N=21 007
NE=103 709)
Combined MVR
(N=14 727
NE=72 680)
Isolated MVR
(N=6280
NE=31 029) P values
Primary payer, n (%) <0.0001
  Medicare/Medicaid 16 243 (77.3) 11 628 (79) 4615 (73.5)
  Private including HMO 4015 (19.1) 2612 (17.7) 1403 (22.3)
  Self-pay/no charge/other 351 (1.7) 228 (1.5) 123 (2)
Median household income, n (%) <0.0001
  1.0–25th percentile 4658 (22.7) 3235 (22.5) 1423 (23.2)
  2.26–50th percentile 5168 (25.1) 3659 (25.4) 1509 (24.6)
  3.51–75th percentile 5162 (25.1) 3637 (25.2) 1525 (24.8)
  4.76–100th percentile 5562 (27.1) 3876 (26.9) 1686 (27.4)
ASD, atrial septal defect; IABP, intra-aortic balloon pump; LV, left ventricular; NE, National Estimate; VSD, ventricular septal defect.
Table 1 Continued
Figure 3 Trend of mortality for patients′ bioprosthetic mitral 
valve replacement (MVR) for mitral regurgitation between 
2003 and 2014.
prevalence of significant clinical morbidities, and this 
prevalence increased overtime (3) In-hospital mortality 
following MVR for MR is high but has improved between 
2003–2014. However, major post-operative morbidities 
remained frequent and did not significantly change 
overtime in the combined MVR group, while the rates of 
stroke and acute kidney injury increased overtime in the 
isolated MVR group. (4) MVR for MR is associated with 
long hospitalizations, frequent intermediate care facility 
utilisation and significant cost. (5) In this large cohort of 
patients undergoing MVR, certain patient’s, hospital and 
procedural characteristics were predictive of in-hospital 
mortality.
Surgical treatment of MR remains underused due to 
the surgical risk in many of MR patients and the lack 
of solid clinical data supporting mitral valve surgery 
for certain indications (eg, secondary MR).8 9 Over the 
past decade, transcatheter mitral valve therapies have 
emerged as promising alternatives to surgery in selected 
patients and is hoped to expand treatment options in 
this undertreated population. The MitraClip device 
demonstrated safety and efficacy in treating severe MR 
in strictly selected patients with suitable anatomy, but also 
highlighted the need for further devices to treat wider 
ranges of MR pathologies.1 This has further fuelled the 
interest in TMVR with several systems currently in EFS 
phases. However, investigational challenges in the TMVR 
field arose due to the complexity and the variability of 
MV disease and its treatment options.3 For example, it 
is unclear whether future randomised trials of TMVR 
would randomise patients against medical therapy or 
surgical MVR. Also, enrolling patients who are suitable 
for MitraClip or surgical repair might be challenging. 
Therefore, conclusive randomised evidence on TMVR 
could be several years ahead. Current outcomes of 
isolated bioprosthetic MVR in patients with MR may 
therefore serve as a benchmark for future investigations. 
Nevertheless, the existing literature on MVR includes 
heterogeneous groups of patients with mechanical MVR, 
infective endocarditis, mitral stenosis and those who are 
undergoing redo mitral valve operations.7 10–13 In this 
study, we attempted to identify a group of patients who 
are similar to those that may be eligible for TMVR (those 
who are undergoing isolated bioprosthetic MVR for MR).
Several intriguing observations can be made by 
analysing the patient’s and procedural characteristics in 
our study: (1) there was a very modest non-significant 
increase in the number of bioprosthetic MVRs for MR 
during the study period, contrary to the sharp increase 
in surgical treatment of other valvular diseases during 
the same period. (2) Patients who undergo MVR in the 
current era have high-risk features including a signifi-
cant prevalence of comorbid conditions (hypertension, 
diabetes, anaemia, atrial fibrillation, prior sternotomy, 
coronary artery disease, coagulopathy and chronic renal 
insufficiency), and the prevalence of these comorbidi-
ties increased overtime, suggesting an increasing trend 
to treated sicker patients. (3) The majority of patients 
with MR undergo MVR concomitant with other cardiac 
surgical procedures, with coronary artery bypass grafting 
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Table 2 Clinical outcomes of patients undergoing surgical bioprosthetic mitral valve replacement (MVR) for mitral 
regurgitation between 2003 and 2014
All patients
(N=21 007
NE=103 709)
Combined MVR
(N=14 727
NE=72 680)
Isolated MVR
(N=6280
NE=31 029) P values
Clinical outcome, n (%)
  In-hospital death 1765 (8.4) 1381 (9.4) 384 (6.1) <0.001
  Vascular complications 903 (4.3) 645 (4.4) 258 (4.1) 0.375
  Vascular complications requiring surgery 473 (2.3) 354 (2.4) 119 (1.9) 0.023
  Permanent pacemaker implantation 2836 (13.5) 2104 (14.3) 732 (11.7) <0.001
  Clinical stroke 533 (2.5) 381 (2.6) 152 (2.4) 0.482
  Acute kidney injury 4844 (23.1) 3659 (24.8) 1185 (18.9) <0.001
  Acute kidney injury requiring dialysis 1028 (4.9) 723 (4.9) 305 (4.9) 0.871
  Blood transfusion 8472 (40.3) 5860 (39.8) 2612 (41.6) 0.015
  Cardiac tamponade 212 (1) 163 (1.1) 49 (0.8) 0.03
  Pneumonia 1347 (6.4) 999 (6.8) 348 (5.5) 0.001
  Prolonged ventilation 1842 (8.8) 1339 (9.1) 503 (8) 0.011
  Wound infection 311 (1.5) 243 (1.7) 68 (1.1) 0.002
  Pulmonary embolism 68 (0.3) 44 (0.3) 24 (0.4) 0.33
  Deep venous thrombosis 158 (0.8) 102 (0.7) 56 (0.9) 0.126
Discharge status, n (%) <0.0001
  Discharged home 12 258 (58.4) 8117 (55.2) 4141 (66.1)
  Discharged SNF/NH/IC 6935 (33.1) 5199 (35.4) 1736 (27.7)
Length of stay, mean (SD), days 15 (13) 15 (14) 13 (12) <0.001
Length of stay >5 days 91 891 (88.6) 65 532 (90.2) 26 359 (84.9) <0.001
Cost of hospitalisation, mean (SD), $ 71 628 (55 652) 75 469 (57 052) 62 443 (50 997) <0.001
IC, intermediate care; NE, National Estimate; NH, nursing home; SNF, skilled nursing facility.
being the most common one. Interestingly, concomitant 
tricuspid valve repair/replacement was undertaken in 
<10% of patients although moderate/severe tricuspid 
regurgitation exists in 25% of patients with MR of any 
aetiology and >50% of patients with secondary MR.3 14 15
In-hospital death occurred in 6.1% and 9.4% of MR 
patients undergoing isolated and combined MVR, 
respectively. Although this study included patients across 
a wide spectrum of risk profiles, it does suggest that even 
in ‘all-comers’ MVR for MR is associated with significant 
in-hospital mortality. This highlights the importance 
of the evolving TMVR field in addressing the critical 
need to find less morbid alternatives for MR patients. It 
also emphasises the contrast between aortic and mitral 
valve diseases. In a contemporary nationwide analysis 
of surgical aortic valve replacement, average in-hospital 
mortality rate in all-comers was 2.5%.16 Rates of postop-
erative morbidities were also high:~5% of patients had 
a dialysis requiring acute kidney injury,>10% required 
permanent pacemaker implantation and >40% had 
blood transfusion. There was also no temporal improve-
ment in the incidence of acute kidney injury and stroke 
in the combined MVR group, while the occurrence of 
these complications increased in the isolated MVR over-
time (online supplementary efigure-2). These data might 
be useful when interpreting the emerging literature of 
the very early experience with TMVR.
Cost and resource utilisation are becoming increas-
ingly important in the era of healthcare reform. Being 
the first widely adopted transcatheter valve therapy, 
TAVR was under special scrutiny due to its added 
incremental costs, but has been found cost-effective in 
high-risk and inoperable patients.17–19 Emerging TMVR 
systems have to be cost-effective to survive an increas-
ingly value-driven healthcare delivery system. Our data 
suggest that MVR is associated with long hospitalisa-
tions, significant cost and high rates of intermediate 
care facility utilisation. Indeed, cost of MVR in our 
study was over twofold higher than cost of aortic valve 
replacement in a contemporary national cost analysis.20 
These data suggest that future TMVR system can be very 
competitive from a cost stand of point. In the largest 
published EFS on TMVR to date, LOS was 9.7±5.9 days 
even though the trial enrolled patients who are at high 
or prohibitive risk for MVR.5
limitations
Our study has several limitations. The NIS is derived 
from hospital claims data without access to individual 
medical records and subject to the shortcomings of 
administrative datasets. However, the Healthcare Cost 
and Utilization Project (HCUP) quality control meas-
ures should minimise these possibilities. Aetiology 
of MR (primary vs secondary), Society of Thoracic 
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Valvular heart disease
Figure 4 Trend of complications for patients undergoing 
bioprosthetic mitral valve replacement (MVR) for mitral 
regurgitation between 2003 and 2014. (A) Trend of 
pacemaker implantation isolated versus combined. (B) 
Trend of acute kidney injury requiring dialysis isolated versus 
combined. (C) Trend of stroke isolated versus combined.
Surgeons (STS) risk score, left ventricular ejection 
fraction, type of bioprosthetic valve used, baseline and 
postoperative echocardiographic data are not captured 
in NIS. Also, details on specific long-term outcomes 
beyond hospital discharge are also not available in NIS. 
Finally, this study included patients who were likely 
deemed acceptable surgical candidates, which may 
underestimate the actual morbidity and mortality of 
the higher-risk patients who are currently being denied 
MVR. Nevertheless, this study provides the largest ‘real-
world’ outcome data on bioprosthetic MVR for MR, 
offering important insights into a cohort of patients 
that will be the focus of multiple investigations in the 
field of TMVR.
ConClusions
Despite temporal improvement in operative mortality, 
isolated bioprosthetic MVR for mitral regurgitation 
remains associated with high morbidity and mortality and 
cost in contemporary practice. These data are useful as 
benchmarks for the emerging TMVR therapies.
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